新辅助药用激光间歇性热疗法阻断PD1,治疗复发性高度质瘤
Carter M Suryadevara1, Hayley Donaldson1, Hammad A Khan1
1Department of Neurosurgery, NYU Grossman School of Medicine, New York, NY, United States.
概括
这项研究表明,将激光间歇性热疗法 (LITT) 与免疫检查点抑制剂 (ICI) 结合起来,是对复发性高度质瘤的安全和可行的治疗方法. 这种组合疗法在减少瘤体积和改善生存结果方面表现出有希望的结果.
科学领域:
- 神经瘤学神经瘤学
- 免疫治疗是一种免疫疗法.
- 最少的侵入性手术是最少的侵入性手术.
背景情况:
- 高度质瘤 (HGG) 由于瘤免疫抑制,很难用免疫检查点抑制剂 (ICI) 治疗.
- 激光间歇性热疗法 (LITT) 可以破坏血脑屏障并创建抗原环境.
- 将LITT与ICI结合起来可能会增强抗瘤免疫反应,并改善HGG的存活率.
研究的目的:
- 评估新辅助剂和辅助剂ICI与LITT相结合的安全性和有效性,用于复发性高度质瘤患者.
- 评估这种联合治疗对放射性瘤体积,无进展生存率 (PFS) 和整体生存率 (OS) 的影响.
主要方法:
- 9名成年患者的回顾病例系列,患有复发的IDH野生型质母细胞瘤,IDH突变高度星细胞瘤或H3K27M突变扩散中线质瘤.
- 患者接受了新辅助抗PD1 ICI,其次是LITT,大多数患者也接受了辅助ICI.
- 通过放射体积细分评估瘤负担;追踪PFS和OS.
主要成果:
- 组合疗法是可行的和安全的,没有术后并发症.
- 虽然LITT后最初的瘤体积增加了,但78%的患者随后表现出加多增强体积的回归.
- 中位数的PFS为5.90个月,中位数的OS为9.97个月,一些患者在卫星病变中经历了显著的反应.
结论:
- 新辅助剂和辅助剂 pembrolizumab 与LITT 结合,是对复发性高度质瘤的安全和可行的方法.
- 组合疗法显示出强烈反应的潜力,可能因分子亚型而异.
- 需要进一步的研究来探索这种治疗策略的协同作用潜力.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.